Abstract: The curative effect of edaravone combined with ozagrel sodium on acute ischemic stroke beyond the time window of thrombolysis was investigated. A total of 100 patients with acute ischemic stroke beyond the time window of thrombolysis were admitted in our hospital from December 2010 to December 2012. The patients were divided into combined treatment group (N = 50) and ozagrel sodium monotherapy group (control group, N = 50). After 14 days' treatment, total effective rate of the combined treatment group (92% , 46/50) was significantly higher than that of the control group (66% , 33/50; χ² = 10.780, P = 0.029). After treatment, the nerve function defect score was significantly improved in comparison with before treatment in both groups, but the improvement in combined treatment group (8.21 ± 3.58) was much better than that in the control group (14.60 ± 4.39; t = 7.976, P = 0.000). Therefore, treatment of edaravone combined with ozagrel sodium for patients with acute ischemic stroke beyond the thrombolytic time window can significantly raise the curative effect and improve the neurological function of these patients.

Key words: Platelet aggregation inhibitors, Antipyrine (Edaravone), Methacrylates (Ozagrel sodium), Brain ischemia, Acute disease

摘要： 观察依达拉奉联合奥扎格雷钠治疗超溶栓时间窗的急性缺血性卒中患者的临床疗效。结果显示，治疗14 d 后依达拉奉联合奥扎格雷钠组（联合治疗组）患者治疗总有效率达92%（46/50），高于奥扎格雷钠单药治疗组的66%（33/50；χ² = 10.780，P = 0.029）；两组患者神经功能明显改善，但联合治疗组［（8.21 ± 3.58）分］优于奥扎格雷单药治疗组［（14.60 ± 4.39）分；t = 7.976，P = 0.000］。提示对于超溶栓时间窗的急性缺血性卒中患者，依达拉奉联合奥扎格雷钠仍可改善神经功能，临床疗效确切。

关键词: 血小板聚集抑制剂, 安替比林（依达拉奉）, 甲基丙烯酸盐（奥扎格雷钠）, 脑缺血, 急性病